Clinical Milestones Sample Clauses

Clinical Milestones. Celgene shall make the following clinical milestone payments to Jounce that are set forth below upon the first achievement by or on behalf of Celgene, its Affiliates or Sublicensees of the clinical milestone events (“Clinical Milestone Events”) set forth below with respect to the first Co-Co Product that achieves such event. For clarity, each milestone set forth below shall be due and payable one time only (regardless of the number of Co-Co Products to achieve any such Clinical Milestone Event). [***] [***] [***] [***] [***] [***]

Clinical Milestones. Event The First Profile to Achieve the Event The Second Profile to Achieve the Event

Clinical Milestones. In consideration for the rights granted to Roche under this Agreement, Roche shall make the following one-time, non-refundable, non-creditable milestone payments to Prothena (up to a total of $[*] per Licensed Product) within [*] after the achievement of the relevant milestone for each Licensed Product and receipt by Roche of an invoice for such amount from Prothena; [*]: (i) [*] $15,000,000 (ii) [*] $[*] (iii) [*] $[*] (iv) [*] $[*] Notwithstanding the foregoing, [*]. The following summarizes the percentage of the payments set forth above that are due with respect to various types of Licensed Compounds: [*] [*]% [*]% [*] [*]% [*]% [*] [*]% [*]% [*] [*]% [*]% The Parties will coordinate to have separate invoices with respect to each milestone payment so that accounting can be allocated appropriately (based on [*] or as otherwise mutually agreed by the JFT) to Roche Nutley and Prothena US for the portion of such milestone payment related to the United States and to Roche Basel and Prothena Ireland for the balance of such milestone payment.

Clinical Milestones. Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

Clinical Milestones. Hyseq will pay to Aurora the following non-creditable, non-refundable milestone payments for the first, and only the first, Hyseq Product within [***] following achievement of each of the following milestone events: Milestone Payment --------- ------- [***]

Clinical Milestones. First site initiation of protocol for Sarcoma Cohort 2 of the Phase I/IIa Sarcoma cancer study (“Sarcoma Cohort 2”) 2.5 First site initiation of protocol for Sarcoma Cohort 3 of the Phase I/IIa Sarcoma study (“Sarcoma Cohort 3”) 2.5 First site initiation of protocol for the Phase I/IIa NSCLC study included in the Initial Development Plan (“NSCLC Study”) 2.5 *** 2.5 *** *** *** *** *** *** *** *** Initiation of companion diagnostic development program as defined in the Initial Development Plan 2.0 *** ***

Clinical Milestones. With respect to each Product (irrespective of the Field of Use in which such event occurs), Novartis shall pay to Celgene the nonrefundable milestone payments set forth below in accordance with Section 8.1(a): ----------------------------------------------------------------------- MILESTONE EVENT MILESTONE PAYMENT ----------------------------------------------------------------------- Submission of IND for Product $3.0 million ----------------------------------------------------------------------- Commencement of Phase II Clinical Trials of Product $2.0 million ----------------------------------------------------------------------- Commencement of Phase III Clinical Trials of Product $4.0 million ----------------------------------------------------------------------- Submission of an NDA for Product $6.0 million ----------------------------------------------------------------------- Regulatory Approval of Product in the United States $8.0 million ----------------------------------------------------------------------- Regulatory Approval of Product in a Major Market $4.0 million other than the United States or Japan ----------------------------------------------------------------------- Regulatory Approval of Product in Japan $2.0 million ----------------------------------------------------------------------- provided, however, that if (i) a Product is abandoned during development after one or more of the milestone payments under this Section 7.2(b) has been made and (ii) a Product comprising or containing a Back-Up Compound is developed for the same indication as the abandoned Product to replace such abandoned Product, then only those milestone payments under this Section 7.2(b) that were not previously made with respect to such abandoned Product shall be payable with respect to the Product comprising or containing such Back-Up Compound. Payments made to Celgene pursuant to this Section 7.2 are non-refundable and may not be credited against any other payments payable by Novartis to Celgene under this Agreement.

Clinical Milestones. JSC decision that cohort 1 of the Phase I/IIa ovarian cancer study included in the Initial Development plan will continue based on an adequate number of positive responses observed in the first 6 patients 2.5 *** *** *** *** *** *** *** *** *** *** *** *** ***Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

Clinical Milestones. Borrower Representative shall have provided Lenders with evidence reasonably satisfactory to Lenders that, on or before the Loan C Commitment Termination Date, Co-Borrowers have achieved positive top line results for either (i) Co-Borrowers’ TTP399 drug or (ii) Co-Borrowers’ TTP273 drug. Lenders acknowledge that Co-Borrowers have, as of the date of this Agreement, satisfied the requirement set forth in this subsection (d).

Clinical Milestones a. With respect to a first Product, Amgen shall pay to GENE the following one-time, non-refundable, non-creditable payments via wire transfer to an account designated by GENE within ***** days following the achievement by Amgen, its Affiliates or sublicensees, of each of the clinical milestones set forth below: (i) US$ ***** (ii) ***** US$ ***** (iii) ***** US$ ***** (iv) ***** US$ ***** (v) ***** US$ ***** Total US$ ***** b. If the first Product to obtain approval by a Regulatory Authority of a Drug Approval Application is a Small Molecule, then with respect to the first Large Molecule for which Amgen files a Drug Approval Application, or if the first Product to obtain approval by a Regulatory Authority of a Drug Approval Application is a Large Molecule, then with respect to the first Small Molecule for which Amgen files a Drug Approval Application, Amgen shall pay to GENE the following one-time, non-refundable, non-creditable payments via wire transfer to an account designated by GENE within thirty (30) days following the achievement by Amgen, its Affiliates or sublicensees, of each of the clinical milestones set forth below: (i) US$ ***** (ii) ***** US$ ***** Total US$ ***** c. Amgen shall provide GENE with prompt written notice upon its achievement of each of the milestones set forth in this Section 8.5. In the event that, notwithstanding the fact that Amgen has not given any such notice, GENE reasonably believes any such milestone payment is due, it shall so notify Amgen and members of the JSC in writing, and shall provide to Amgen and members of the JSC the data and information demonstrating that the conditions for payment have been achieved. Within thirty (30) days of its receipt of such notice, the JSC shall review the data and information and determine whether or not the conditions for payment have been achieved pursuant to Section 2.4. Any negative determination shall be accompanied by a detailed explanation of the reasons therefore.